FDA advisers are voting on whether to recommend approval for Grail Inc.'s Galleri blood test, which detects up to 50 types of cancer

BusinessSep 23 at 5:27 AM – Sep 23 at 10:12 AM17 outlets

NPR

Will FDA advisers recommend a multi-cancer blood test for approval? They'll vote Sep 23 at 6:00 AM

Quartz

FDA advisers are voting on Grail's multicancer blood test as Medicare coverage hangs in the balance Sep 23 at 9:30 AM

The Independent

Grail's cancer blood test faces high-stakes FDA review Sep 23 at 9:22 AM

Boston Herald

Grail’s cancer blood test faces high-stakes FDA review Sep 23 at 5:27 AM

Hartford Courant

Grail’s cancer blood test faces high-stakes FDA review Sep 23 at 5:27 AM

Local 10 WPLG

Grail's cancer blood test faces high-stakes FDA review Sep 23 at 9:40 AM

MarketWatch

FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow. Sep 23 at 8:39 AM

Orlando Sentinel

Grail’s cancer blood test faces high-stakes FDA review Sep 23 at 5:27 AM

South Florida Sun Sentinel

Grail’s cancer blood test faces high-stakes FDA review Sep 23 at 5:27 AM

The Mercury News

Grail’s cancer blood test faces high-stakes FDA review Sep 23 at 2:27 AM

The Philadelphia Inquirer

Grail's cancer blood test faces high-stakes FDA review Sep 23 at 9:22 AM

The San Diego Union-Tribune

Grail’s cancer blood test faces high-stakes FDA review Sep 23 at 2:27 AM

Times Union

Grail's cancer blood test faces high-stakes FDA review seen Sep 23 at 9:29 AM

Toronto Star

Grail’s cancer blood test faces high-stakes FDA review seen Sep 23 at 9:39 AM

Winnipeg Free Press

Grail’s cancer blood test faces high-stakes FDA review Sep 23 at 9:23 AM

WRAL

Grail's cancer blood test faces high-stakes FDA review seen Sep 23 at 10:05 AM

Times Colonist

Grail's cancer blood test faces high-stakes FDA review Sep 23 at 9:23 AM